YARROW BIOSCIENCE, INC. Operating Expenses
YARROW BIOSCIENCE, INC. (YARW) reported Operating Expenses of $21.93 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-03-03
- YARROW BIOSCIENCE, INC. operating expenses for the quarter ending 2019-12-31 was $21.93M, a 18.93% increase year-over-year.
- YARROW BIOSCIENCE, INC. operating expenses for the quarter ending 2019-09-30 was $17.43M, a 27.18% increase year-over-year.
- YARROW BIOSCIENCE, INC. operating expenses for the quarter ending 2019-06-30 was $17.22M, a 10.87% decline year-over-year.
- YARROW BIOSCIENCE, INC. operating expenses for the quarter ending 2019-03-31 was $19.67M, a 43.39% increase year-over-year.
- YARROW BIOSCIENCE, INC. operating expenses for fiscal 2019 was $76.24M, a 16.98% increase from fiscal 2018.
- YARROW BIOSCIENCE, INC. operating expenses for fiscal 2018 was $65.17M, a 90.71% increase from fiscal 2017.
- YARROW BIOSCIENCE, INC. operating expenses for fiscal 2017 was $34.17M, a 127.74% increase from fiscal 2016.
- YARROW BIOSCIENCE, INC. operating expenses for fiscal 2016 was $15.01M, a 225.65% increase from fiscal 2015.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $21.93M 10-K · filed 2020-03-03 | $39.36M derived: sum of 2 quarters · filed 2020-03-03 | $56.57M derived: sum of 3 quarters · filed 2020-03-03 | $76.24M 10-K · filed 2020-03-03 | |
| 2019-09-30 | $17.43M 10-K · filed 2020-03-03 | $34.64M derived: sum of 2 quarters · filed 2020-03-03 | $54.31M 10-Q · filed 2019-10-31 | $72.75M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2019-06-30 | $17.22M 10-K · filed 2020-03-03 | $36.88M 10-Q · filed 2019-08-01 | $55.33M derived: sum of 3 quarters · filed 2020-03-03 | $69.03M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2019-03-31 | $19.67M 10-K · filed 2020-03-03 | $38.11M derived: sum of 2 quarters · filed 2020-03-03 | $51.81M derived: sum of 3 quarters · filed 2020-03-03 | $71.13M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2018-12-31 | $18.44M 10-K · filed 2020-03-03 | $32.14M derived: sum of 2 quarters · filed 2020-03-03 | $51.46M derived: sum of 3 quarters · filed 2020-03-03 | $65.17M 10-K · filed 2020-03-03 | |
| 2018-09-30 | $13.70M 10-K · filed 2020-03-03 | $33.02M derived: sum of 2 quarters · filed 2020-03-03 | $46.73M 10-Q · filed 2019-10-31 | $58.99M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2018-06-30 | $19.32M 10-K · filed 2020-03-03 | $33.03M 10-Q · filed 2019-08-01 | $45.28M derived: sum of 3 quarters · filed 2020-03-03 | $54.53M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2018-03-31 | $13.72M 10-K · filed 2020-03-03 | $25.97M derived: sum of 2 quarters · filed 2020-03-03 | $35.21M derived: sum of 3 quarters · filed 2020-03-03 | $41.89M derived: sum of 4 quarters · filed 2020-03-03 | |
| 2017-12-31 | $12.25M 10-K · filed 2019-02-28 | $21.50M derived: sum of 2 quarters · filed 2019-02-28 | $28.17M derived: sum of 3 quarters · filed 2019-02-28 | $34.17M 10-K · filed 2020-03-03 | |
| 2017-09-30 | $9.24M 10-K · filed 2019-02-28 | $15.92M derived: sum of 2 quarters · filed 2019-02-28 | $21.92M 10-Q · filed 2018-11-07 | $27.30M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $6.67M 10-K · filed 2019-02-28 | $6.67M 10-K · filed 2018-03-28 | $12.68M 10-Q · filed 2018-08-01 | $18.05M derived: sum of 3 quarters · filed 2019-02-28 | $21.75M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $6.00M 10-K · filed 2019-02-28 | $11.38M derived: sum of 2 quarters · filed 2019-02-28 | $15.08M derived: sum of 3 quarters · filed 2019-02-28 | $18.71M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $5.37M 10-K · filed 2018-03-28 | $9.07M derived: sum of 2 quarters · filed 2018-03-28 | $12.71M derived: sum of 3 quarters · filed 2018-03-28 | $15.01M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $3.70M 10-K · filed 2018-03-28 | $7.33M derived: sum of 2 quarters · filed 2018-03-28 | $9.63M derived: sum of 3 quarters · filed 2018-03-28 | ||
| 2016-06-30 | $3.64M 10-K · filed 2018-03-28 | $5.93M derived: sum of 2 quarters · filed 2018-03-28 | |||
| 2016-03-31 | $2.30M 10-K · filed 2018-03-28 | ||||
| 2015-12-31 | $4.61M 10-K · filed 2018-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |